{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:30Z","timestamp":1780586070612,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100030684","name":"Maruho","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01768-0","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:47:09Z","timestamp":1778870829000},"page":"3201-3214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post\u00a0Hoc Analysis of Pooled Data from Two Phase III Clinical Trials"],"prefix":"10.1007","volume":"16","author":[{"given":"Makoto","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6964-0796","authenticated-orcid":false,"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kabashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"1768_CR1","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H, et\u00a0al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296\u2013304.","journal-title":"Br J Dermatol"},{"key":"1768_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/exd.13236","volume":"27","author":"S Oyama","year":"2018","unstructured":"Oyama S, Kitamura H, Kuramochi T, et\u00a0al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018;27:14\u201321.","journal-title":"Exp Dermatol"},{"key":"1768_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","volume":"383","author":"K Kabashima","year":"2020","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141\u201350.","journal-title":"N Engl J Med"},{"key":"1768_CR4","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.20873","volume":"186","author":"K Kabashima","year":"2022","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01 and JP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two Phase III, long-term studies. Br J Dermatol. 2022;186:642\u201351.","journal-title":"Br J Dermatol"},{"key":"1768_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s13555-023-00901-7","volume":"13","author":"K Kabashima","year":"2023","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Nemolizumab improves patient-reported symptoms of atopic dermatitis with pruritus: post\u00a0hoc analysis of a Japanese Phase III randomized controlled trial. Dermatol Ther (Heidelb). 2023;13:997\u20131011.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1768_CR6","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1111\/1346-8138.17544","volume":"52","author":"H Saeki","year":"2025","unstructured":"Saeki H, Ohya Y, Arakawa H, et\u00a0al. English version of clinical practice guidelines for the management of atopic dermatitis 2024. J Dermatol. 2025;52:e70\u2013142.","journal-title":"J Dermatol"},{"key":"1768_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100457","volume":"4","author":"Y Masuo","year":"2025","unstructured":"Masuo Y, Yonekura S, Nakajima S, Sawada Y, Kabashima K. Clinical factors predicting nemolizumab response in atopic dermatitis. J Allergy Clin Immunol Glob. 2025;4:100457.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"1768_CR8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/1346-8138.17626","volume":"52","author":"A Sugiyama","year":"2025","unstructured":"Sugiyama A, Yano-Takamori A, Kojima K, et\u00a0al. Characteristics of suitable cases for treatment with nemolizumab based on clinical findings and cutaneous adverse events. J Dermatol. 2025;52:740\u20133.","journal-title":"J Dermatol"},{"key":"1768_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206575","volume":"12","author":"S Ferrucci","year":"2023","unstructured":"Ferrucci S, Casazza G, Zussino M, Tavecchio S, Marzano AV, Tedeschi M. Predictive factors of early response to dupilumab in patients with moderate-to-severe atopic dermatitis. J Clin Med. 2023;12:6575.","journal-title":"J Clin Med"},{"key":"1768_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.anai.2022.05.025","volume":"129","author":"JJ Wu","year":"2022","unstructured":"Wu JJ, Hong CH, Merola JF, et\u00a0al. Predictors of nonresponse to dupilumab in patients with atopic dermatitis: a machine learning analysis. Ann Allergy Asthma Immunol. 2022;129:354\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1768_CR11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1111\/jdv.19909","volume":"38","author":"K Ashizaki","year":"2024","unstructured":"Ashizaki K, Ishikawa T, Nomura Y. Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning. J Eur Acad Dermatol Venereol. 2024;38:2286\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1768_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2336\/nishinihonhifu.73.278","volume":"73","author":"M Kawashima","year":"2011","unstructured":"Kawashima M, Nakagawa H. Olopatadine hydrochloride in children: evidenced efficacy and safety for atopic dermatitis treatment in a randomized, multicenter, double-blind, parallel group comparative study. Nishinihon J Dermatol. 2011;73:278\u201389.","journal-title":"Nishinihon J Dermatol"},{"key":"1768_CR13","volume-title":"Classification and regression trees","author":"L Breiman","year":"1984","unstructured":"Breiman L, Friedman J, Olshen RA, Stone CJ. Classification and regression trees. Belmont: Wadsworth; 1984."},{"key":"1768_CR14","volume-title":"Information retrieval","author":"CJ van Rijsbergen","year":"1979","unstructured":"van Rijsbergen CJ. Information retrieval. London: Butterworths; 1979."},{"key":"1768_CR15","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511809071","volume-title":"Introduction to information retrieval","author":"CD Manning","year":"2008","unstructured":"Manning CD, Raghavan P, Sch\u00fctze H. Introduction to information retrieval. Cambridge: Cambridge University Press; 2008."},{"key":"1768_CR16","doi-asserted-by":"crossref","unstructured":"Javed Mehedi Shamrat FM, Ghosh P, Sadek MH, Kazi MA, Shultana S. Implementation of machine learning algorithms to detect the prognosis rate of kidney disease. IEEE international conference for innovation in technology (INOCON), Bengaluru. 2020. pp. 1\u20137.","DOI":"10.1109\/INOCON50539.2020.9298026"},{"key":"1768_CR17","unstructured":"Jacobs MC. Regression trees versus stepwise regression. UNF graduate theses and dissertations. 1992. pp. 145. https:\/\/digitalcommons.unf.edu\/etd\/145"},{"key":"1768_CR18","unstructured":"Lundberg SM, Lee SI. A unified approach to interpreting model predictions. 31st conference on neural information processing systems (NIPS 2017), Long Beach, CA. 2017. pp. 4768\u201377."},{"key":"1768_CR19","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, et\u00a0al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"key":"1768_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","volume":"5","author":"HA Verduzco","year":"2020","unstructured":"Verduzco HA, Shirazian S. CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management. Kidney Int Rep. 2020;5:1387\u2013402.","journal-title":"Kidney Int Rep"},{"key":"1768_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s11255-021-02904-9","volume":"54","author":"G Gembillo","year":"2022","unstructured":"Gembillo G, Siligato R, Cernaro V, et\u00a0al. Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients. Int Urol Nephrol. 2022;54:395\u2013403.","journal-title":"Int Urol Nephrol"},{"key":"1768_CR22","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, et\u00a0al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68:995\u20131005.","journal-title":"Dig Dis Sci"},{"key":"1768_CR23","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1007\/s10620-019-06009-3","volume":"65","author":"L Kaps","year":"2020","unstructured":"Kaps L, Grambihler A, Yemane B, et\u00a0al. Symptom burden and treatment response in patients with primary biliary cholangitis (PBC). Dig Dis Sci. 2020;65:3006\u201313.","journal-title":"Dig Dis Sci"},{"key":"1768_CR24","doi-asserted-by":"crossref","unstructured":"Sasaki W, Saito R, Suzuki K, et al. Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan. J Dermatol. 2026;53:399\u2013409.","DOI":"10.1111\/1346-8138.17877"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01768-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:54:04Z","timestamp":1780584844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1768"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01768-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Makoto Kawashima received personal fees from Maruho Co., Ltd., and Sato Pharmaceutical Co., Ltd. Tomoya Maeda, Kotaro Iwasaki, Noriaki Kaneda, and Masashi Takizawa are employees of Maruho Co., Ltd. Kenji Kabashima has received consulting fees, honoraria, grant support, and\/or lecture fees from AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Pfizer, Procter & Gamble, Sanofi, Regeneron, Taiho, and Torii Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The present study was a post\u00a0hoc analysis of pooled data from two previously conducted Japanese Phase III clinical trials, Study-JP01 (JapicCTI-173740) and Study-JP02 (JapicCTI-183894), and involved no new recruitment, intervention, or contact with participants. Accordingly, additional ethical approval for the present analysis was not required. The original clinical trials were conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, and all other applicable regulatory requirements. The trial protocols and related documentation were approved by the IRBs at each participating center, including the Sapporo Skin Clinic IRB. Written informed consent was obtained from all patients or their legal guardians prior to initiation of any study procedures and treatment. Publicly available ethics committee reference numbers\/IRB numbers for the original trials could not be identified from the published reports.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}